Foghorn Therapeutics Inc. Accounts Payable
Foghorn Therapeutics Inc. (FHTX) had Accounts Payable of $3.21 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $3.21M.
- 2026-03-31: Accounts Payable, Current $3.32M.
- 2025-12-31: Accounts Payable, Current $4.27M.
- 2025-09-30: Accounts Payable, Current $3.21M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $3.21M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.32M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.27M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.21M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $3.32M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $4.07M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.79M 10-K · filed 2026-03-11 |
| 2024-09-30 | $3.45M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $4.81M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.63M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $6.26M 10-K · filed 2025-03-06 |
| 2023-09-30 | $6.50M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $6.93M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $7.29M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $5.41M 10-K · filed 2024-03-07 |
| 2022-09-30 | $5.26M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.63M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $5.07M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.82M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.82M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.41M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $2.91M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $3.68M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $3.55M 10-Q · filed 2020-12-04 |
| 2019-12-31 | $3.44M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |